Normunity: coaxing T cells to enter tumors 

Boston-based Normunity is helping to restore T cells’ normal ability to infiltrate and destroy tumors via a class of therapies dubbed “immune normalizers.” It debuted on Tuesday with a Canaan Ventures-led $65 million series A as the latest company to leverage the work of scientific co-founder Lieping Chen, an immunologist at the Yale School of Medicine. 

The company has developed technologies for deconstructing the mechanisms by which T cells enter tumors to discover targets that can warm up “cold” tumors that fail to trigger a strong immune response. The immune normalizers are meant to restore natural cancer immunity...